(Q38175163)

30 August 2017

title

Minimal clinically important differences in pharmacological trials (English)

1 reference

30 August 2017

1 reference

4

Marc Decramer

1 reference

30 August 2017

Paul W Jones

1

1 reference

30 August 2017

Kai M Beeh

2

1 reference

30 August 2017

Kenneth R Chapman

3

1 reference

30 August 2017

Donald A Mahler

5

1 reference

30 August 2017

Jadwiga A Wedzicha

6

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

American Journal of Respiratory and Critical Care Medicine

30 August 2017

published in

1 reference

30 August 2017

volume

189

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

250-255

1 reference

Measurement of health status. Ascertaining the minimal clinically important difference

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Challenges associated with estimating minimal clinically important differences in COPD-the NHLBI perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Methods to explain the clinical significance of health status measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Minimal clinically important difference--exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Do we know the minimal clinically important difference (MCID) for COPD exacerbations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

A measure of quality of life for clinical trials in chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

The minimal important difference of exercise tests in severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

No room to breathe: the importance of lung hyperinflation in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Understanding the minimum clinically important difference: a review of concepts and methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Premature discontinuation during the UPLIFT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201310-1863PP

10.1164/RCCM.201310-1863PP

21 January 2018

Identifiers

DOI

1 reference

release_c2l5q5xpijgpjowoicblbrfs6y

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c2l5q5xpijgpjowoicblbrfs6y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference